Allogene Therapeutics Investor Relations Material
Latest events
Q2 2025
Allogene Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Allogene Therapeutics Inc
Access all reports
Allogene Therapeutics Inc is a biotechnology company focused on developing allogeneic CAR T cell therapies for cancer treatment. The company’s approach uses gene-editing and cell engineering technologies to produce off-the-shelf immunotherapies designed to target various hematologic and solid tumors. Its operations span research, clinical trials, and manufacturing. Allogene Therapeutics Inc is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Key slides for Allogene Therapeutics Inc
Corporate Presentation
Allogene Therapeutics Inc
Corporate Presentation
Allogene Therapeutics Inc
Latest articles
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
Ticker symbol
ALLO
Country
🇺🇸 United States